Health and Healthcare
Despite Target Cuts, Analysts Stick With Incyte for Big Upside
Published:
Last Updated:
Incyte Corp. (NASDAQ: INCY) took it on the chin this past week following the announcement that its Phase 2 trial of ruxolitinib would be stopped. This was detrimental to the stock, but a few analysts took a deeper look at it and realized that it might not be as bad as initially thought.
On Wednesday, the company announced that the Phase 2 sub-study of ruxolitinib or placebo in combination with regorafenib in patients with relapsed or refractory metastatic colorectal cancer and high C-reactive protein (CRP) will be stopped early.
The decision to stop the sub-study was made after a planned interim analysis of the high CRP subgroup demonstrated that ruxolitinib plus regorafenib did not show a sufficient level of efficacy to warrant continuation.
As a result, shares initially dropped as low as 14% off this level, pushing a new 52-week low. However after analysts came to bat for this biotech, shares made a healthy bounce in Friday’s trading session.
Shares of Incyte were trading at $70.56 on Friday’s close, with a consensus analyst price target of $116.77 (this may change) and a 52-week trading range of $64.51 to $133.62.
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.